Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Castle Biosciences Inc.

< Previous 1 2 Next >
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports Third Quarter 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports Second Quarter 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Honored with Top Workplaces Awards
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.